# AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

> **NCT05377658** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AK104
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05377658
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377658, "AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05377658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*